Clostridium Difficile Toxins a and/or B Antigen and Epitope Antibody, and Pharmaceutical Uses Thereof

4) A pharmaceutical composition for generating a neutralizing antibody directed against Clostridium difficile toxins A and/or B and comprising:

• at least two different polypeptides, each polypeptide comprising a portion of Clostridium difficile toxins A and/or B sequence, said portion of toxins A and/or B sequence being an epitope for anti-toxins A and/or B antibody, said portion comprising a sequence being SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3, SEQ ID NO:
• 4, or any combination thereof, and
• a pharmaceutically acceptable carrier.

7) A vaccine composition for prevention or treatment of Clostridium difficile infection comprising:

• at least one polypeptide which comprises a portion of Clostridium difficile toxins A and/or B sequence, said portion of toxins A and/or B sequence being an epitope for anti-toxins A and/or B antibody, said portion comprising a sequence being SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3, SEQ ID NO:
• 4, or any combination thereof;
• and
• a pharmaceutically acceptable adjuvant.

9) A nucleic acid vaccine composition for prevention or treatment of Clostridium difficile infection comprising:

• nucleic acids encoding at least one polypeptide which comprises a portion of Clostridium difficile toxins A and/or B sequence, said portion of toxins A and/or B sequence being an epitope for anti-toxins A and/or B antibody;
• said portion comprising a sequence being SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3, SEQ ID NO:
• 4, or any combination thereof;
• and
• a pharmaceutically acceptable adjuvant.

11) A method of generating a neutralizing antibody directed against Clostridium difficile toxins A and/or B, the method comprising:

• i) administrating to a host an isolated polypeptide comprising a portion of the Clostridium difficile toxins A and/or B sequence, said portion comprising a sequence being SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3, SEQ ID NO:
• 4, or any combination thereof, for generating antibodies in the host;
• and
• (ii) obtaining the antibodies from the host.

12) The method of claim , wherein the portion of the Clostridium difficile toxins A and/or B sequence comprises a combination of SEQ ID NO:

• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3 and SEQ ID NO:
• 4.

14) A purified antibody adapted for binding to a toxins A and/or B peptide, the peptide comprises a sequence being SEQ ID NO:

• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3, SEQ ID NO:
• 4, or any combination thereof.

19) An antibody composition for prevention or treatment of Clostridium difficile infection, comprising different antibodies adapted for binding to at least two epitopes of toxins A and/or B, said at least two epitopes comprising a sequence being SEQ ID NO:

• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3, SEQ ID NO:
• 4, or any combination thereof.

21) A pharmaceutical composition for the prevention or the treatment of Clostridium difficile toxins A and/or B intoxication, said composition comprising at least one antibody adapted for binding to at least one epitope of toxins A and/or B, said at least one epitope comprising a sequence being SEQ ID NO:

• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3, SEQ ID NO:
• 4, or any combination thereof;
• and a pharmaceutically acceptable carrier.